Literature DB >> 10146876

Roxithromycin vs cefaclor.

T Hughes1, W G Scott, H M Scott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 10146876     DOI： 10.2165/00019053-199304050-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  6 in total

1.  A comparison of tiaprofenic acid, mefenamic acid and placebo in the treatment of dysmenorrhoea in general practice.

Authors:  M W Tilyard; S M Dovey
Journal:  Aust N Z J Obstet Gynaecol       Date:  1992-05       Impact factor: 2.100

2.  A randomized double-blind controlled trial of roxithromycin and cefaclor in the treatment of acute lower respiratory tract infections in general practice.

Authors:  M W Tilyard; S M Dovey
Journal:  Diagn Microbiol Infect Dis       Date:  1992 May-Jun       Impact factor: 2.803

3.  Treatment of postmenopausal osteoporosis with calcitriol or calcium.

Authors:  M W Tilyard; G F Spears; J Thomson; S Dovey
Journal:  N Engl J Med       Date:  1992-02-06       Impact factor: 91.245

4.  Roxithromycin versus cefaclor in lower respiratory tract infection: a general practice pharmacoeconomic study.

Authors:  W G Scott; M W Tilyard; S M Dovey; B Cooper; H M Scott
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

5.  Cefaclor safety profile: a ten-year review.

Authors:  D L Hyslop
Journal:  Clin Ther       Date:  1988       Impact factor: 3.393

6.  An evaluation of tolerance of roxithromycin in adults.

Authors:  F Blanc; J D'Enfert; S Fiessinger; A Lenoir; M Renault; Y Rezvani
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790
  6 in total
  1 in total

Review 1.  Cost-effective treatment of lower respiratory tract infections.

Authors:  J C Garrelts; A M Herrington
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.